Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Not yet recruitingOBSERVATIONAL
Enrollment

5,000

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

February 1, 2029

Study Completion Date

February 1, 2029

Conditions
HBVHCC
Interventions
DRUG

nucleoside analogues or interferon

ETV、TDF、TAF、TAF、IFN-a-2b

Trial Locations (10)

200040

Huashan Hospital, Shanghai

210000

Jiangsu Province Hospital, Nanjing

221000

the Affiliated Hosptial of Xuzhou Medical University, Xuzhou

230022

The First Affiliated Hospital of Anhui Medical University, Hefei

350004

The First Affiliated Hospital of Fujian Medical University, Fuzhou

430000

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

650100

The First People's Hospital Of YunNan, Kunming

710061

First Affiliated Hospital Xi'an Jiaotong University, Xi’an

Unknown

Shandong Provincial Hospital of Shandong University, Jinan

The Third People's Hospital of Taiyuan, Taiyuan

All Listed Sponsors
collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

collaborator

First Affiliated Hospital of Fujian Medical University

OTHER

collaborator

The Third People's Hospital of Taiyuan

OTHER

collaborator

The First People's Hospital of Yunnan

OTHER

collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

lead

Wen-hong Zhang

OTHER

NCT05965388 - Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy | Biotech Hunter | Biotech Hunter